DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

AstraZeneca plc (ADR) (NYSE: AZN)



company name or ticker
Company Photos
(Click to zoom)

QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on L

QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on Liquid Biopsies in Collaboration With AstraZeneca

3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015

Clinical-stage biotechs tend to bubble to the top of the list of best performing healthcare stocks. Here are three names to watch in 2015 and beyond.

I Think This Next-Generation Diabetes Drug Offers the Greatest Growth Potential

Three Motley Fool analysts weigh in with the companies they think could benefit from launching next generation diabetes treatments.

3 Pharma Stocks That Soared Past Pfizer in 2014 - Analyst Blog

Isis Pharmaceuticals Improves 2014 Outlook, Shares Up - Analyst Blog

What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts

Does AstraZeneca PLC Stock Offer a Golden Opportunity in 2015?

AstraZeneca would appear to be set to have a slow 2015. But that doesn't mean investors should sleep on this stock. Here's why.

History Suggests MannKind Corporation's Afrezza Could Already Be Doomed

Afrezza could be a game-changing inhaled diabetes therapy, but it must overcome an obstacle that crushed previous potential game changers.

Is AbbVie Inc. Ripe for a Buyout?

After failing to complete a buyout of Irish biopharma Shire, AbbVie was reported to be a potential takeover target. Is this top drugmaker an attractive acquisition target for growth-starved big pharma in 2015?

Five Market Predictions For 2015

See More Articles...